eFFECTOR is developing a novel class of small molecule drugs to selectively regulate translation (protein synthesis) with an initial emphasis on cancer. Kevan Shokat, ex-Intellikine (a portfolio company that Abingworth exited successfully in 2012), is one of the scientific founders.

LocationSan Diego, California
CEOSteve Worland
Partner Ken Haas
Websitewww.effector.com